Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.

Cancer medicine - 1 Feb 2020

Sakhdari Ali, Thakral Beenu, Loghavi Sanam, Kanagal-Shamanna Rashmi, Yin C Cameron, Zuo Zhuang, Routbort Mark J, Luthra Rajyalakshmi, Medeiros L Jeffrey, Wang Sa A, Patel Keyur P, Ok Chi Young

Abstract excerpt

Adult T-cell acute lymphoblastic leukemia (T-ALL) is a heterogeneous group of acute leukemias that account for about one third of all cases of Philadelphia chromosome (Ph)-negative ALL. Recently, a molecular classifier using the mutational status of NOTCH1, FBXW7, RAS, and PTEN (NFRP) has been shown to distinguish low- vs high-risk groups in adult T-ALL patients treated using the Berlin-Frankfurt-Münster ALL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclophosphamide
Share to Dexamethasone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Electronic Health Records

Share to GTP Phosphohydrolases

Share to Neoplasm Recurrence, Local

Share to Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 31804006
DOI: 10.1002/cam4.2757
PMCID: PMC6997098

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.PMID 31804006Read ↗

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.Semantic proximity Read ↗

TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.Semantic proximity Read ↗

Mutational spectrum of adult T-ALL.Semantic proximity Read ↗

Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.Semantic proximity Read ↗

Optimized outcome prediction of oncogenetic mutations in non-early T-cell precursor acute lymphoblastic leukemia.Semantic proximity Read ↗

Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukemia.Semantic proximity Read ↗

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine.Semantic proximity Read ↗

Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia.Semantic proximity Read ↗

Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.Semantic proximity Read ↗

Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.Semantic proximity Read ↗

Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL.Semantic proximity Read ↗

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.